Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage...
Pregnancy
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase...
INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing
SARASOTA, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare...
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts,...
SlimJaro Botanical Approaches Gain Interest in 2025 for Inflammation-Related Metabolic Wellness
A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns....
Carrot Unveils New Program to Redefine Metabolic-Fertility Care
Sprints Program will Combat Leading Causes of Infertility, Reduce IVF Cycles, and Help Achieve Healthier Pregnancies – Faster – with...
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE)...
Pinnacle Fertility Appoints Dr. Richard Scott to Board of Directors, Signaling Leap Forward in Scientific and Strategic Excellence
SCOTTSDALE, Ariz., June 27, 2025 /PRNewswire/ -- Pinnacle Fertility proudly announces the appointment of Dr. Richard Scott to its Board...
Baylor Genetics Applauds New Guidance from American Academy of Pediatrics for Genome and Exome Sequencing to be used as First-Tier Tests for Children with Certain Developmental Delays
Guidance also outlines metabolic evaluation – like Baylor Genetics’ unique Global MAPS® untargeted metabolite screen – as second-tier testHOUSTON, June...
INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent
SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare...
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the...
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or...
GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025
GE HealthCare continues to advance precision care in cardiology through innovative molecular imaging solutions to help support early diagnosis, tailored...
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent...
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared...
Maven Clinic Partners with ŌURA to Bring Data-Driven, Personalized Health Support to Women and Families
Partnership combines Oura's real-time health insights with Maven's virtual care to deliver proactive, connected support and better outcomes from fertility...
New Scientific Research Funding Available to Eliminate Pre-Term Deliveries from Preeclampsia
MELBOURNE, Fla., June 17, 2025 /PRNewswire/ -- The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance...
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed...